News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Enzon Pharmaceuticals, Inc. Presents New Data on Its LNA Programs
October 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its LNA technology platform at the 4th Annual Meeting of Oligonucleotide Therapeutics Society (OTS) in Boston, Massachusetts.
Twitter
LinkedIn
Facebook
Email
Print
Events
Preclinical
MORE ON THIS TOPIC
Cancer
BMS scraps Orum’s targeted degrader after reviewing Phase 1 data
September 18, 2026
·
1 min read
·
Tristan Manalac
Deals
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
September 17, 2026
·
2 min read
·
Michael Gibney
Cardiovascular disease
Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
September 17, 2026
·
2 min read
·
Tristan Manalac
Insights
When vision fades: Rethinking wet AMD and the durability gap
September 17, 2026
·
1 min read
·
Jennifer C. Smith-Parker
